0001213900-26-057782
SEC filingEnlivex Therapeutics Ltd. received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement over 30 consecutive business days, with 180 days until November 9, 2026, to regain compliance.
Enlivex Ltd. disclosed receiving a formal notification from Nasdaq Stock Market LLC indicating noncompliance with Listing Rule 5550(a)(2), as the closing bid price of its ordinary shares fell below the $1.00 minimum over the prior 30 business days. This triggers an initial 180-calendar-day grace period ending November 9, 2026, during which the Company must sustain a $1.00 closing price for at least 10 consecutive business days to regain compliance and receive written confirmation from Nasdaq. Failure to comply opens eligibility for a second 180-day extension, contingent on satisfying all other Nasdaq Capital Market listing criteria except bid price, notifying Nasdaq of intent to cure—potentially via reverse stock split—and demonstrating capability to resolve the issue. Delisting notification would follow if the second period fails, with appeal rights to a Hearings Panel. Critically, the notice imposes no immediate restrictions on listing status, share trading, or operations, allowing Enlivex to focus on remediation while continuing as a quality longevity company advancing Allocetra immunotherapy and its RAIN token prediction markets treasury strategy.